之江生物
(688317)
| 流通市值：30.41亿 | | | 总市值：30.41亿 |
| 流通股本：1.90亿 | | | 总股本：1.90亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 53,388,232.75 | 25,419,230.44 | 124,818,624.7 | 90,432,870.13 |
| 营业总成本 | 99,895,489.51 | 57,769,206 | 191,336,369.74 | 142,500,155.06 |
| 其他经营收益 | | | | |
| 营业利润 | -40,394,114.46 | -23,585,534.64 | -47,574,372.37 | -27,556,230.78 |
| 利润总额 | -39,613,389.81 | -23,896,668.03 | -42,116,446.49 | -25,938,257.2 |
| 净利润 | -40,589,405.04 | -25,510,247.42 | -34,297,566.55 | -29,377,855.95 |
| 每股收益 | | | | |
| 其他综合收益 | -3,069,771.16 | -2,004,953.83 | -988,720.13 | 42,222.59 |
| 综合收益总额 | -43,659,176.2 | -27,515,201.25 | -35,286,286.68 | -29,335,633.36 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,877,530,648.64 | 2,914,156,150.92 | 2,986,196,949.69 | 2,937,857,696.86 |
| 非流动资产: | | | | |
| 非流动资产合计 | 778,752,727.92 | 792,570,364.29 | 777,603,047.8 | 783,244,118.42 |
| 资产总计 | 3,656,283,376.56 | 3,706,726,515.21 | 3,763,799,997.49 | 3,721,101,815.28 |
| 流动负债: | | | | |
| 流动负债合计 | 113,373,897.98 | 115,705,426.03 | 126,582,842.47 | 127,385,314.87 |
| 非流动负债: | | | | |
| 非流动负债合计 | 282,288,227.71 | 288,424,154.93 | 288,368,242.95 | 199,786,727.43 |
| 负债合计 | 395,662,125.69 | 404,129,580.96 | 414,951,085.42 | 327,172,042.3 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,260,621,250.87 | 3,302,596,934.25 | 3,348,848,912.07 | 3,393,929,772.98 |
| 股东权益合计 | 3,260,621,250.87 | 3,302,596,934.25 | 3,348,848,912.07 | 3,393,929,772.98 |
| 负债和股东权益合计 | 3,656,283,376.56 | 3,706,726,515.21 | 3,763,799,997.49 | 3,721,101,815.28 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 93,979,615.34 | 41,051,800.19 | 258,857,309.99 | 172,091,272.35 |
| 经营活动现金流出小计 | 82,375,408.17 | 44,711,541.1 | 192,003,878.28 | 139,418,855.68 |
| 经营活动产生的现金流量净额 | 11,604,207.17 | -3,659,740.91 | 66,853,431.71 | 32,672,416.67 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,131,581,306.06 | 263,513,630.78 | 1,117,856,922.98 | 695,338,538.3 |
| 投资活动现金流出小计 | 1,161,373,531 | 352,544,270.9 | 1,424,581,231.33 | 1,014,576,344.21 |
| 投资活动产生的现金流量净额 | -29,792,224.94 | -89,030,640.12 | -306,724,308.35 | -319,237,805.91 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 0 | - | 297,000,000 | 198,000,000 |
| 筹资活动现金流出小计 | 52,534,691.72 | 22,230,905.94 | 267,357,026.23 | 224,847,753.82 |
| 筹资活动产生的现金流量净额 | -52,534,691.72 | -22,230,905.94 | 29,642,973.77 | -26,847,753.82 |
| 汇率变动对现金及现金等价物的影响 | -30,645,147.64 | -15,069,979.84 | -23,008,255.17 | -9,676,055.88 |
| 现金及现金等价物净增加额 | -101,367,857.13 | -129,991,266.81 | -233,236,158.04 | -323,089,198.94 |
| 期末现金及现金等价物余额 | 2,448,572,198.09 | 2,422,741,216.05 | 2,549,940,055.22 | 2,460,303,439.58 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -101,367,857.13 | - | -233,236,158.04 | - |